Solid Biosciences Inc (NASDAQ: SLDB) is 28.62% higher on its value in year-to-date trading and has touched a low of $2.88 and a high of $15.05 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The SLDB stock was last observed hovering at around $5.73 in the last trading session, with the day’s loss setting it -0.59%.
Currently trading at $5.14, the stock is -4.09% and 22.77% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.03 million and changing -10.21% at the moment leaves the stock -17.46% off its SMA200. SLDB registered -54.91% loss for a year compared to 6-month loss of -34.54%. The firm has a 50-day simple moving average (SMA 50) of $4.1907 and a 200-day simple moving average (SMA200) of $6.233425.
The stock witnessed a 55.91% gain in the last 1 month and extending the period to 3 months gives it a 0.68%, and is -6.45% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.23% over the week and 13.47% over the month.
Solid Biosciences Inc (SLDB) has around 100 employees, a market worth around $398.70M and $0.00M in sales. Distance from 52-week low is 78.65% and -65.81% from its 52-week high. The company has generated returns on investments over the last 12 months (-78.72%).
The EPS is expected to grow by 28.30% this year
127.0 institutions hold shares in Solid Biosciences Inc (SLDB), with institutional investors hold 62.51% of the company’s shares. The shares outstanding are 77.49M, and float is at 68.10M with Short Float at 10.75%. Institutions hold 62.23% of the Float.
Solid Biosciences Inc (SLDB) Insider Activity
The most recent transaction is an insider purchase by Kahn Clare, the company’s Director. SEC filings show that Kahn Clare bought 1,860 shares of the company’s common stock on Mar 11 ’25 at a price of $5.34 per share for a total of $9924.0. Following the purchase, the insider now owns 2960.0 shares.
Solid Biosciences Inc disclosed in a document filed with the SEC on Feb 19 ’25 that Bain Capital Life Sciences Inv (10% Owner) bought a total of 1,000,000 shares of the company’s common stock. The trade occurred on Feb 19 ’25 and was made at $4.03 per share for $4.03 million. Following the transaction, the insider now directly holds 5.03 million shares of the SLDB stock.
Still, SEC filings show that on Feb 19 ’25, PERCEPTIVE ADVISORS LLC (Director) acquired 5,000,000 shares at an average price of $4.03 for $20.15 million. The insider now directly holds 11,833,539 shares of Solid Biosciences Inc (SLDB).
